WHO ICTRP trial
Molecular mechanism and further treatment of EGFR-TKI resistance in advanced…
ChiCTR1800017533 · Chinese Clinical Trial Registry (ChiCTR) · Recruiting
Key facts
| Trial ID | ChiCTR1800017533 |
|---|---|
| Public title | Molecular mechanism and further treatment of EGFR-TKI resistance in advanced lung adenocarcinoma with EGFR positive mutation |
| Scientific title | Molecular mechanism and further treatment of EGFR-TKI resistance in advanced lung adenocarcinoma with EGFR positive mutation |
| Primary sponsor | The second hospital of Tianjin Medical University |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Recruiting |
| Study type | Relative factors research |
| Phase | Basic Science |
| Countries | China |
| Conditions | lung adenocarcinoma |
| Interventions | Case series:Nil |
| Registration date | Aug 2, 2018 |
| Target size | Case series:100 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: